Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia

Completed · Phase 4

Conditions studied: Tachycardia, Ventricular

In brief

Determine effects of remifentanil conscious sedation in patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent premature ventricular contractions (PVCs) of non-ischemic origin

Key facts

Study ID

NCT01901575

Run by

NYU Langone Health

People needed

16

Starts

2011-07-01

Expected to finish

2013-04-01

Last updated by the study team

2018-01-02

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients scheduled to undergo EP studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin
• Patients between 18 and 65
• ASA 1-3

You may not qualify if…

• ASA 4 and 5
• Age 18 and 65

Where it is running

• NYU Langone Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.